share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

SEC announcement ·  Jan 18 13:00
Summary by Futu AI
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on January 16, 2024, involving the sale of 20,000 shares of common stock. The shares were sold at a price of $62.5029 per share, resulting in a total transaction value of $1,250,058. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at $19.12 each. Following the transactions, Kulkarni's direct holdings in the company amount to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
CRISPR Therapeutics CEO Samarth Kulkarni completed a stock transaction on January 16, 2024, involving the sale of 20,000 shares of common stock. The shares were sold at a price of $62.5029 per share, resulting in a total transaction value of $1,250,058. Prior to this sale, Kulkarni exercised options to acquire the same number of shares at $19.12 each. Following the transactions, Kulkarni's direct holdings in the company amount to 187,377 shares. Additionally, Kulkarni has an indirect beneficial ownership of 200,000 shares through The Kulkarni 2023 GRAT.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.